X4 Pharmaceuticals, Inc. logo

X4 Pharmaceuticals, Inc.

X4 Pharmaceuticals is developing novel small molecule therapeutics designed to improve immune cell trafficking including the ability for T-cells to track and destroy cancer cells.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttp://www.x4pharma.com
Disease Focus
Development Stage
STOCK CODENon Listed
Address
955 Massachusetts Avenue, 4th Floor, MA, 02139
Cambridge
United States
Email
Contact Number
+1 857-529-8300

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/x4-pharmaceuticals” connections=”true” suffix=””]

X4 Pharmaceuticals small molecule drug candidates inhibit C-X-C receptor type 4 (CXCR4), a receptor over-expressed in many cancers. Inhibition of CXCR4 is designed to block non-cancerous immunosuppressive and pro-angiogenic cells from populating the tumor, disrupting the cancer microenvironment and restoring normal immune surveillance functions.

In Nov 2017, X4 Pharmaceuticals, raised $27 Mn in Series B financing. Earlier, In 2015, X4 raised $37.5 Mn in Series A Round, Earlier X4 has raised over $1.5 Mn in seed investment from angel investors, including Henri Termeer, previous CEO of Genzyme, and Michael Bonney, previous CEO of Cubist.